Michael V. Martin, Salvador Aguilar-Rosas, Katka Franke, Mark Pieterse, Jamie van Langelaar, Renee RCE. Schreurs, Maarten F. Bijlsma, Marc G. Besselink, Jan Koster, Wim Timens, Mustafa Khasraw, David M. Ashley, Stephen T. Keir, Christian H. Ottensmeier, Emma V. King, Joanne Verheij, Cynthia Waasdorp, Peter J.M. Valk, Sem AG. Engels, Ellen Oostenbach, Jip T. van Dinter, Damon A. Hofman, Juk Yee Mok, Wim J.E. van Esch, Hanneke Wilmink, Kim Monkhorst, Henk M.W. Verheul, Dennis Poel, T Jeroen N. Hiltermann, Léon C. van Kempen, Harry JM. Groen, Joachim G.J.V. Aerts, Sebastiaan van Heesch, Bob Lowenberg, Ronald Plasterk, Wigard P. Kloosterman
{"title":"构成肿瘤框架组的新开放阅读框肽是癌症免疫疗法新抗原的丰富来源","authors":"Michael V. Martin, Salvador Aguilar-Rosas, Katka Franke, Mark Pieterse, Jamie van Langelaar, Renee RCE. Schreurs, Maarten F. Bijlsma, Marc G. Besselink, Jan Koster, Wim Timens, Mustafa Khasraw, David M. Ashley, Stephen T. Keir, Christian H. Ottensmeier, Emma V. King, Joanne Verheij, Cynthia Waasdorp, Peter J.M. Valk, Sem AG. Engels, Ellen Oostenbach, Jip T. van Dinter, Damon A. Hofman, Juk Yee Mok, Wim J.E. van Esch, Hanneke Wilmink, Kim Monkhorst, Henk M.W. Verheul, Dennis Poel, T Jeroen N. Hiltermann, Léon C. van Kempen, Harry JM. Groen, Joachim G.J.V. Aerts, Sebastiaan van Heesch, Bob Lowenberg, Ronald Plasterk, Wigard P. Kloosterman","doi":"10.1158/2326-6066.cir-23-0158","DOIUrl":null,"url":null,"abstract":"Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate cancer whole genome and long-read transcript sequencing to identify the collection of novel open reading frame peptides (NOPs) expressed in tumors, termed the framome. NOPs represent tumor-specific peptides that are different from wild-type proteins and may be strongly immunogenic. We describe an uncharacterized class of hidden NOPs, which derive from structural genomic variants involving an upstream protein coding gene driving expression and translation of non-coding regions of the genome downstream of a rearrangement breakpoint. NOPs represent a vast amount of possible neoantigens particularly in tumors with many (complex) structural genomic variants and a low number of missense mutations. We show that NOPs are immunogenic and epitopes derived from NOPs can bind to MHC class I molecules. Finally, we provide evidence for the presence of memory T-cells specific for hidden NOPs in lung cancer patient peripheral blood.","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":null,"pages":null},"PeriodicalIF":8.1000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The neo-open reading frame peptides that comprise the tumor framome are a rich source of neoantigens for cancer immunotherapy\",\"authors\":\"Michael V. Martin, Salvador Aguilar-Rosas, Katka Franke, Mark Pieterse, Jamie van Langelaar, Renee RCE. Schreurs, Maarten F. Bijlsma, Marc G. Besselink, Jan Koster, Wim Timens, Mustafa Khasraw, David M. Ashley, Stephen T. Keir, Christian H. Ottensmeier, Emma V. King, Joanne Verheij, Cynthia Waasdorp, Peter J.M. Valk, Sem AG. Engels, Ellen Oostenbach, Jip T. van Dinter, Damon A. Hofman, Juk Yee Mok, Wim J.E. van Esch, Hanneke Wilmink, Kim Monkhorst, Henk M.W. Verheul, Dennis Poel, T Jeroen N. Hiltermann, Léon C. van Kempen, Harry JM. Groen, Joachim G.J.V. Aerts, Sebastiaan van Heesch, Bob Lowenberg, Ronald Plasterk, Wigard P. Kloosterman\",\"doi\":\"10.1158/2326-6066.cir-23-0158\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate cancer whole genome and long-read transcript sequencing to identify the collection of novel open reading frame peptides (NOPs) expressed in tumors, termed the framome. NOPs represent tumor-specific peptides that are different from wild-type proteins and may be strongly immunogenic. We describe an uncharacterized class of hidden NOPs, which derive from structural genomic variants involving an upstream protein coding gene driving expression and translation of non-coding regions of the genome downstream of a rearrangement breakpoint. NOPs represent a vast amount of possible neoantigens particularly in tumors with many (complex) structural genomic variants and a low number of missense mutations. We show that NOPs are immunogenic and epitopes derived from NOPs can bind to MHC class I molecules. Finally, we provide evidence for the presence of memory T-cells specific for hidden NOPs in lung cancer patient peripheral blood.\",\"PeriodicalId\":9474,\"journal\":{\"name\":\"Cancer immunology research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":8.1000,\"publicationDate\":\"2024-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer immunology research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2326-6066.cir-23-0158\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer immunology research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2326-6066.cir-23-0158","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
鉴定作为治疗靶点的免疫原性癌症新抗原具有挑战性。在这里,我们整合了癌症全基因组测序和长线程转录本测序,以鉴定肿瘤中表达的新型开放阅读框肽(NOPs)集合,称为 "framome"。NOPs 代表肿瘤特异性多肽,它们不同于野生型蛋白,可能具有很强的免疫原性。我们描述了一类尚未定性的隐性 NOPs,它们来自结构基因组变异,涉及上游蛋白编码基因驱动基因组重排断点下游非编码区的表达和翻译。NOPs 代表了大量可能的新抗原,尤其是在具有大量(复杂)结构基因组变异和少量错义突变的肿瘤中。我们的研究表明,NOPs 具有免疫原性,NOPs 衍生的表位可与 MHC I 类分子结合。最后,我们提供了肺癌患者外周血中存在特异于隐藏 NOPs 的记忆 T 细胞的证据。
The neo-open reading frame peptides that comprise the tumor framome are a rich source of neoantigens for cancer immunotherapy
Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate cancer whole genome and long-read transcript sequencing to identify the collection of novel open reading frame peptides (NOPs) expressed in tumors, termed the framome. NOPs represent tumor-specific peptides that are different from wild-type proteins and may be strongly immunogenic. We describe an uncharacterized class of hidden NOPs, which derive from structural genomic variants involving an upstream protein coding gene driving expression and translation of non-coding regions of the genome downstream of a rearrangement breakpoint. NOPs represent a vast amount of possible neoantigens particularly in tumors with many (complex) structural genomic variants and a low number of missense mutations. We show that NOPs are immunogenic and epitopes derived from NOPs can bind to MHC class I molecules. Finally, we provide evidence for the presence of memory T-cells specific for hidden NOPs in lung cancer patient peripheral blood.
期刊介绍:
Cancer Immunology Research publishes exceptional original articles showcasing significant breakthroughs across the spectrum of cancer immunology. From fundamental inquiries into host-tumor interactions to developmental therapeutics, early translational studies, and comprehensive analyses of late-stage clinical trials, the journal provides a comprehensive view of the discipline. In addition to original research, the journal features reviews and opinion pieces of broad significance, fostering cross-disciplinary collaboration within the cancer research community. Serving as a premier resource for immunology knowledge in cancer research, the journal drives deeper insights into the host-tumor relationship, potent cancer treatments, and enhanced clinical outcomes.
Key areas of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and insightful clinical investigations with immunological implications.